Founded in 1983, the Gentest brand initially focused on the use of cultured human cells in GLP genotoxicity assays. In 1985, the company expanded research activities into the area of xenobiotic metabolism by developing cytochrome P450 cDNA-expression approaches. This led to the first commercial offering of cDNA-expressed human cytochrome P450 enzymes in 1990. Since that time, the range of Gentest offerings has increased dramatically, from recombinant systems to in vivo-like systems like primary hepatocytes. Now, as part of Corning Life Sciences, the Gentest offerings continue to grow, helping you stay on the leading edge of drug discovery and development.
Our scientists are internationally recognized as leaders and innovators in cytochrome P450 cDNA-expression, in vitro xenobiotic metabolism, and drug transporter techniques. Our demonstrated commitment to research has been rewarded by the receipt of several competitive NIH grants. The results and applications of our research are reported in peer reviewed journals and at international symposia by our scientists, colleagues, and customers interested in xenobiotic metabolism.
